406 related articles for article (PubMed ID: 29370211)
1. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
Hayes AR; Brungs D; Pavlakis N
PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for advanced prostate cancer.
Macherey S; Monsef I; Jahn F; Jordan K; Yuen KK; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006250. PubMed ID: 29278410
[TBL] [Abstract][Full Text] [Related]
8. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for advanced prostate cancer.
Yuen KK; Shelley M; Sze WM; Wilt T; Mason MD
Cochrane Database Syst Rev; 2006 Oct; (4):CD006250. PubMed ID: 17054286
[TBL] [Abstract][Full Text] [Related]
10. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
11. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
12. Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials.
Menshawy A; Mattar O; Abdulkarim A; Kasem S; Nasreldin N; Menshawy E; Mohammed S; Abdel-Maboud M; Gadelkarim M; El Ashal GG; Elgebaly AS
Support Care Cancer; 2018 Apr; 26(4):1029-1038. PubMed ID: 29387997
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prevention of bone complications from prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
[TBL] [Abstract][Full Text] [Related]
17. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.
Ng TL; Tu MM; Ibrahim MFK; Basulaiman B; McGee SF; Srikanthan A; Fernandes R; Vandermeer L; Stober C; Sienkiewicz M; Jeong A; Saunders D; Awan AA; Hutton B; Clemons MJ
Support Care Cancer; 2021 Feb; 29(2):925-943. PubMed ID: 32535678
[TBL] [Abstract][Full Text] [Related]
18. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
Peddi P; Lopez-Olivo MA; Pratt GF; Suarez-Almazor ME
Cancer Treat Rev; 2013 Feb; 39(1):97-104. PubMed ID: 22898302
[TBL] [Abstract][Full Text] [Related]
20. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]